The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study

Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Orphanet journal of rare diseases Jg. 17; H. 1; S. 155 - 9
Hauptverfasser:	Fletcher, Simon, Jenner, Kathryn, Pembroke, Luke, Holland, Michael, Khair, Kate
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 04.04.2022 Springer Nature B.V BMC
Schlagworte:	Adult Aged Altruism Clinical trial Clinical trials Clinical Trials as Topic Decision making Emotions Factor IX deficiency Family - psychology Gene therapy Genetic Therapy Haematology Haemophilia A Haemophilia B Hemophilia Hemophilia A - drug therapy Hemophilia A - therapy Human Genetics Humans Immunosuppression Informed consent Medical research Medicine Medicine & Public Health Middle Aged Pharmacology/Toxicology Qualitative Research Rare diseases Steroids Transfection Young Adult United Kingdom > UK Genetic therapy Informed consent Clinical trial Haemophilia A Haemophilia B Decision making
ISSN:	1750-1172, 1750-1172
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families. Results Sixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4 years (range 23–75 years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56 years (range 1–10 years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process. Conclusion The results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research.
AbstractList	Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families. Results Sixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4 years (range 23–75 years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56 years (range 1–10 years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process. Conclusion The results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research. Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families.BACKGROUNDGene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families.Sixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4 years (range 23-75 years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56 years (range 1-10 years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process.RESULTSSixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4 years (range 23-75 years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56 years (range 1-10 years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process.The results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research.CONCLUSIONThe results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research. Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families. Results Sixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4 years (range 23–75 years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56 years (range 1–10 years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process. Conclusion The results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research. Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families. Sixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4 years (range 23-75 years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56 years (range 1-10 years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process. The results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research. Abstract Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families. Results Sixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4 years (range 23–75 years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56 years (range 1–10 years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process. Conclusion The results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research.
ArticleNumber	155
Author	Pembroke, Luke Khair, Kate Jenner, Kathryn Holland, Michael Fletcher, Simon
Author_xml	– sequence: 1 givenname: Simon orcidid: 0000-0001-9018-6176 surname: Fletcher fullname: Fletcher, Simon email: sfletcher26@aol.com organization: Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals NHS Foundation Trust – sequence: 2 givenname: Kathryn orcidid: 0000-0002-2704-0606 surname: Jenner fullname: Jenner, Kathryn organization: Haemnet – sequence: 3 givenname: Luke orcidid: 0000-0002-2024-6898 surname: Pembroke fullname: Pembroke, Luke organization: Haemnet – sequence: 4 givenname: Michael orcidid: 0000-0002-9173-4100 surname: Holland fullname: Holland, Michael organization: Haemnet – sequence: 5 givenname: Kate orcidid: 0000-0003-2001-5958 surname: Khair fullname: Khair, Kate organization: Haemnet
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35379267$$D View this record in MEDLINE/PubMed
BookMark	eNp9Uk1v1DAUjFARbRf-AAdkiQsHArYT2wkHJFQVqFSJSzlbL87bxFXWDra3dP8FPxmn20LbQw_-0Hszo7HfHBcHzjssiteMfmCskR8jqyivSsr5soQs-bPiiClBS8YUP7h3PyyOY7yktBYVbV4Uh5WoVMulOir-XIxI8HrGYNEZjMSvyYx-npD8tmkkI-DGz6OdLBBwPUkj2kDWsMmVPXpAh0s5wLwj1hEgZrLOGphICjbvEVOybvhEAg6QO24gxrsU_PR-4ZHTa5s1zI7EtO13L4vna5givro9V8XPr6cXJ9_L8x_fzk6-nJdG1DSVpq-h7hVQSSvktJdcdBINUmmk6aWgFetEX5multg2nTEMqKrXjQJTK1CqWhVne93ew6Weg91A2GkPVt8UfBg0hGTNhJpxrEUnFMVe1qJpu6ZvDEAPLTKFSmStz3utedttsDeYXwfTA9GHHWdHPfgr3bQNU_Vi5t2tQPC_thiT3thocJrAod9GzWWtOKtYKzP07SPopd8Gl78qowRnUsiMXBVv7jv6Z-Vu8BnQ7AEm-BgDrrWxCZJdBgN20ozqJWN6nzGd86VvMqZ5pvJH1Dv1J0nVnhQz2A0Y_tt-gvUXL8vmKw
CitedBy_id	crossref_primary_10_1007_s44337_025_00376_9 crossref_primary_10_2478_jhp_2021_0019 crossref_primary_10_1016_j_jtha_2022_12_027 crossref_primary_10_1080_16078454_2024_2439061 crossref_primary_10_1016_j_rpth_2024_102640 crossref_primary_10_1055_s_0044_1785483 crossref_primary_10_1111_hae_14887 crossref_primary_10_2478_jhp_2024_0012 crossref_primary_10_1182_bloodadvances_2025016642 crossref_primary_10_1186_s13023_023_02977_y crossref_primary_10_1111_hae_14822 crossref_primary_10_1186_s13023_024_03181_2 crossref_primary_10_1016_j_jtha_2024_07_029 crossref_primary_10_2478_jhp_2022_0021 crossref_primary_10_1016_j_gim_2023_100831 crossref_primary_10_1080_17474086_2023_2276206 crossref_primary_10_2478_jhp_2023_0017 crossref_primary_10_2478_jhp_2025_0001 crossref_primary_10_2478_jhp_2024_0007 crossref_primary_10_1016_j_rpth_2023_102237 crossref_primary_10_2147_PPA_S406894 crossref_primary_10_2478_jhp_2024_0006 crossref_primary_10_1016_j_blre_2023_101118 crossref_primary_10_1186_s13023_024_03068_2 crossref_primary_10_1016_j_jtha_2023_12_018 crossref_primary_10_1177_10600280231202247 crossref_primary_10_1111_hae_15108 crossref_primary_10_33590_emjhematol_QMQG5189 crossref_primary_10_1007_s00277_023_05277_4 crossref_primary_10_1111_hae_70008 crossref_primary_10_1111_jvh_13882 crossref_primary_10_2478_jhp_2022_0011 crossref_primary_10_1186_s13023_022_02543_y crossref_primary_10_1111_hae_15125 crossref_primary_10_1186_s13023_022_02313_w
Cites_doi	10.1182/blood-2018-07-820720 10.1111/hae.14046 10.1111/hae.14378 10.1111/hae.12121 10.17225/jhp00174 10.1111/hae.14188 10.2147/PPA.S239810 10.1111/hae.14190 10.1056/NEJMoa1703068 10.1016/S2352-3026(19)30054-7 10.1182/blood.V130.Suppl_1.3331.3331 10.1111/hae.14012 10.1002/ajh.24218 10.1111/j.1365-2141.2010.08139.x 10.1182/BLOOD-2018-99-115495 10.1080/13696998.2021.1891088 10.1182/blood.2019001869 10.1093/med/9780190459277.001.0001 10.46743/2160-3715/2015.2281 10.1056/NEJMoa1108046 10.1093/oso/9780195168655.003.0038 10.1038/mt.2010.274 10.1177/26330040211047244 10.1056/nejme078098 10.1056/NEJMoa1708483 10.7748/nr2007.07.14.4.7.c6039 10.1007/s40271-019-00395-6 10.1111/hae.13673 10.1056/NEJMoa1407309 10.1093/hmg/ddz157
ContentType	Journal Article
Copyright	The Author(s) 2022 2022. The Author(s). 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1186/s13023-022-02256-2
DatabaseName	Springer Nature OA Free Journals (WRLC) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1750-1172
EndPage	9
ExternalDocumentID	oai_doaj_org_article_12e45b570ed64589b8d8caada9e17e75 PMC8981747 35379267 10_1186_s13023_022_02256_2
Genre	Journal Article
GeographicLocations	United Kingdom--UK
GeographicLocations_xml	– name: United Kingdom--UK
GrantInformation_xml	– fundername: uniQure Biophpharma BV grantid: 2-061.003 – fundername: ; grantid: 2-061.003
GroupedDBID	--- 0R~ 123 29N 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ISR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c540t-cd4a4d7a0603e20d625b6ece06c6cd65031b5d3cb46e98bcc1a074f87ac47a773
IEDL.DBID	DOA
ISICitedReferencesCount	30
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000778122900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1750-1172
IngestDate	Tue Oct 14 19:03:01 EDT 2025 Tue Nov 04 01:59:25 EST 2025 Wed Oct 01 14:25:13 EDT 2025 Sun Oct 19 01:28:51 EDT 2025 Mon Jul 21 05:46:05 EDT 2025 Sat Nov 29 03:40:44 EST 2025 Tue Nov 18 21:32:21 EST 2025 Sat Sep 06 07:29:05 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Genetic therapy Informed consent Clinical trial Haemophilia A Haemophilia B Decision making
Language	English
License	2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c540t-cd4a4d7a0603e20d625b6ece06c6cd65031b5d3cb46e98bcc1a074f87ac47a773
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-2024-6898 0000-0003-2001-5958 0000-0002-2704-0606 0000-0001-9018-6176 0000-0002-9173-4100
OpenAccessLink	https://doaj.org/article/12e45b570ed64589b8d8caada9e17e75
PMID	35379267
PQID	2652165621
PQPubID	76088
PageCount	9
ParticipantIDs	doaj_primary_oai_doaj_org_article_12e45b570ed64589b8d8caada9e17e75 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8981747 proquest_miscellaneous_2647213196 proquest_journals_2652165621 pubmed_primary_35379267 crossref_citationtrail_10_1186_s13023_022_02256_2 crossref_primary_10_1186_s13023_022_02256_2 springer_journals_10_1186_s13023_022_02256_2
PublicationCentury	2000
PublicationDate	2022-04-04
PublicationDateYYYYMMDD	2022-04-04
PublicationDate_xml	– month: 04 year: 2022 text: 2022-04-04 day: 04
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Orphanet journal of rare diseases
PublicationTitleAbbrev	Orphanet J Rare Dis
PublicationTitleAlternate	Orphanet J Rare Dis
PublicationYear	2022
Publisher	BioMed Central Springer Nature B.V BMC
Publisher_xml	– name: BioMed Central – name: Springer Nature B.V – name: BMC
References	P Batty (2256_CR29) 2019; 28 W Meisbach (2256_CR21) 2020; 14 FG Miller (2256_CR23) 2008 AC Nathwani (2256_CR30) 2011; 19 S Pipe (2256_CR10) 2019; 6 N Li (2256_CR7) 2021; 24 AC Nathwani (2256_CR11) 2011; 365 DN Berg (2256_CR25) 1985 A Farrugia (2256_CR6) 2013; 19 M Richards (2256_CR4) 2010; 149 L Woollard (2256_CR36) 2021; 2 J Oldenburg (2256_CR8) 2017; 377 RH Bernard (2256_CR38) 2012 GQ Perin (2256_CR13) 2018; 33 EC van Balen (2256_CR20) 2020; 13 K Brown (2256_CR16) 2018; 17 G Pierce (2256_CR17) 2019; 25 PI Fusch (2256_CR37) 2015; 20 M Manco-Johnson (2256_CR3) 2007; 357 AC Nathwani (2256_CR12) 2014; 371 S Rangarajan (2256_CR14) 2017; 377 R Curtis (2256_CR2) 2015; 90 A Srivastava (2256_CR5) 2020; 26 K Khair (2256_CR35) 2021; 27 KA High (2256_CR28) 2018; 132 2256_CR34 E Whitmore (2256_CR24) 1994 G Young (2256_CR9) 2019; 134 2256_CR32 S Rangarajan (2256_CR27) 2018; 24 R Dresser (2256_CR33) 2016 2256_CR15 E van Overbeeke (2256_CR18) 2020; 27 JS Stonebraker (2256_CR1) 2020; 27 E Aradom (2256_CR22) 2021 M Simmons (2256_CR26) 2007; 14 S Pipe (2256_CR31) 2017; 130 S Fletcher (2256_CR19) 2021; 27 35379279 - Orphanet J Rare Dis. 2022 Apr 4;17(1):154. doi: 10.1186/s13023-022-02313-w
References_xml	– volume: 17 start-page: 541 year: 2018 ident: 2256_CR16 publication-title: Nat Rev Drug Discov doi: 10.1182/blood-2018-07-820720 – volume: 26 start-page: S1 year: 2020 ident: 2256_CR5 publication-title: Haemophilia doi: 10.1111/hae.14046 – volume: 27 start-page: 760 year: 2021 ident: 2256_CR19 publication-title: Haemophilia doi: 10.1111/hae.14378 – volume: 19 start-page: e228 year: 2013 ident: 2256_CR6 publication-title: Haemophilia doi: 10.1111/hae.12121 – year: 2021 ident: 2256_CR22 publication-title: J Haemophilia Pract doi: 10.17225/jhp00174 – volume: 27 start-page: 120 year: 2021 ident: 2256_CR35 publication-title: Haemophilia doi: 10.1111/hae.14188 – volume: 33 start-page: 407 year: 2018 ident: 2256_CR13 publication-title: Blood doi: 10.1182/blood-2018-07-820720 – volume: 14 start-page: 767 year: 2020 ident: 2256_CR21 publication-title: Patient Preference Adherence doi: 10.2147/PPA.S239810 – volume: 27 start-page: 129 year: 2020 ident: 2256_CR18 publication-title: Haemophilia doi: 10.1111/hae.14190 – volume: 377 start-page: 809 year: 2017 ident: 2256_CR8 publication-title: NEJM doi: 10.1056/NEJMoa1703068 – volume: 6 start-page: e295 issue: 6 year: 2019 ident: 2256_CR10 publication-title: Lancet Haematol doi: 10.1016/S2352-3026(19)30054-7 – volume: 130 start-page: S3331 year: 2017 ident: 2256_CR31 publication-title: Blood doi: 10.1182/blood.V130.Suppl_1.3331.3331 – start-page: 82 volume-title: Participation in human inquiry year: 1994 ident: 2256_CR24 – volume: 24 start-page: S65 year: 2018 ident: 2256_CR27 publication-title: Haemophilia – volume-title: Social research methods: qualitative and quantitative approaches year: 2012 ident: 2256_CR38 – volume: 27 start-page: 591 year: 2020 ident: 2256_CR1 publication-title: Haemophilia doi: 10.1111/hae.14012 – volume: 90 start-page: S11 year: 2015 ident: 2256_CR2 publication-title: Am J Hematol doi: 10.1002/ajh.24218 – volume: 149 start-page: 498 year: 2010 ident: 2256_CR4 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2010.08139.x – volume: 132 start-page: 92 year: 2018 ident: 2256_CR28 publication-title: Blood doi: 10.1182/BLOOD-2018-99-115495 – ident: 2256_CR32 – volume: 24 start-page: 363 year: 2021 ident: 2256_CR7 publication-title: J Med Econ doi: 10.1080/13696998.2021.1891088 – volume: 134 start-page: 2127 year: 2019 ident: 2256_CR9 publication-title: Blood doi: 10.1182/blood.2019001869 – ident: 2256_CR15 – volume-title: Silent partners: human subjects and research ethics year: 2016 ident: 2256_CR33 doi: 10.1093/med/9780190459277.001.0001 – ident: 2256_CR34 – volume: 20 start-page: 1408 year: 2015 ident: 2256_CR37 publication-title: Qual Rep doi: 10.46743/2160-3715/2015.2281 – volume: 365 start-page: 2357 year: 2011 ident: 2256_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa1108046 – start-page: 397 volume-title: The Oxford textbook of clinical research ethics year: 2008 ident: 2256_CR23 doi: 10.1093/oso/9780195168655.003.0038 – volume: 19 start-page: 876 year: 2011 ident: 2256_CR30 publication-title: Mol Ther doi: 10.1038/mt.2010.274 – volume: 2 start-page: 1 year: 2021 ident: 2256_CR36 publication-title: Ther Adv Rare Dis doi: 10.1177/26330040211047244 – volume: 357 start-page: 535 issue: 6 year: 2007 ident: 2256_CR3 publication-title: N Engl J Med doi: 10.1056/nejme078098 – volume: 377 start-page: 2519 year: 2017 ident: 2256_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa1708483 – volume: 14 start-page: 7 issue: 4 year: 2007 ident: 2256_CR26 publication-title: Nurse Res doi: 10.7748/nr2007.07.14.4.7.c6039 – volume: 13 start-page: 201 year: 2020 ident: 2256_CR20 publication-title: Patient doi: 10.1007/s40271-019-00395-6 – volume: 25 start-page: 189 year: 2019 ident: 2256_CR17 publication-title: Haemophilia doi: 10.1111/hae.13673 – start-page: 21 volume-title: Exploring clinical methods for social research year: 1985 ident: 2256_CR25 – volume: 371 start-page: 1994 year: 2014 ident: 2256_CR12 publication-title: N Engl J Med doi: 10.1056/NEJMoa1407309 – volume: 28 start-page: R95 year: 2019 ident: 2256_CR29 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddz157 – reference: 35379279 - Orphanet J Rare Dis. 2022 Apr 4;17(1):154. doi: 10.1186/s13023-022-02313-w
SSID	ssj0045308
Score	2.4896493
Snippet	Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the... Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of... Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the... Abstract Background Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to...
SourceID	doaj pubmedcentral proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	155
SubjectTerms	Adult Aged Altruism Clinical trial Clinical trials Clinical Trials as Topic Decision making Emotions Factor IX deficiency Family - psychology Gene therapy Genetic Therapy Haematology Haemophilia A Haemophilia B Hemophilia Hemophilia A - drug therapy Hemophilia A - therapy Human Genetics Humans Immunosuppression Informed consent Medical research Medicine Medicine & Public Health Middle Aged Pharmacology/Toxicology Qualitative Research Rare diseases Steroids Transfection Young Adult
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgixAX3o9AQUbiRqMmjl_hgijaigurCoHUm-XHpF2pJMtmi-i_4CdjO06q5dELh1xiO7Ljz-PxzPgbhF7pgjTaBD68iuqccm1z01DImdGWU8dLXZiYbEIsFvL4uD5KBrc-hVWOMjEKatfZYCPfJ9xvNF75IOXb1bc8ZI0K3tWUQuM62glMZXSGdg7mi6NPoyymrCrkeFVG8v0-uOmC35KEh_GcbG1HkbX_b6rmnxGTv7lN4250eOd_x3EX3U56KH43AOceugbtfXTzY_K0P0A_PX4wTDzIPe4aPESb42C6xacavnarYI3RWLcOR4cDjuaS5VDbIxPwcL3rAi9brPF4CxPHVCG4hxhz_Qav4WTIU4FT4PxeaIfnPyJT6AWOFLgP0ZfD-ef3H_KUvSG3Xgvc5NZRTZ3QBS8qIIXzBy3DwULBLbfOK4ZVaZirrKEcamms9bAQtJFCWyq0ENUjNGu7Fp4gbAvHdOBGBFpT8N-swHo1zlIjmtI1NEPlOInKJmrzkGHjTMUjjuRqmHjlJ13FiVckQ6-nNquB2OPK2gcBG1PNQModX3TrE5XWuCoJUGaYKMBxymRtpJNWa6drKAUIlqHdERIqSYpeXeIhQy-nYr_Gg-NGt9CdhzrUH9SDsMzQ4wGIU08qVomacJEhsQXRra5ul7TL08gjLmvpz6O-5d4I5stu_ftXPL16FM_QLRLXV4hv2kWzzfocnqMb9vtm2a9fpPX5C5vmReU priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQQYhLeUOgoEHiRiPy8CvcALXiQoV4qTdrbE_alSCpNtuK_gt-MraTLFooSHDIJR5HlvPNeOwZf8PYUyyqFm3kw6s55lyiy23LKRcWneRelljYVGxCHRzow8Pm3XQpbJiz3eeQZLLUSa21fD7EEFuMOVbxETIPhvdyWO50VMf3Hz7P9peLutDz9ZgL-20sQYmp_yL38vcsyV9CpWkF2r_-f2O_wbYnjxNejhC5yS5Rd4tdfTvF1G-z7wEpQGvG4wH6Fsa8coiHtHCM9LU_iecuCNh5SKEFSAcji1E6YJBgvMh1DosOEOb7lpCKgsBAKbv6BSzpaKxIAVOK_G7sB3vfEifoOSSy2zvs0_7ex9dv8qlOQ-6Cv7fKnefIvcJCFjVVhQ9bKivJUSGddD64gHVpha-d5ZIabZ0LAFC81QodV6hUfZdtdX1H9xm4wguMLIjEG07hmzW54LA5blVb-pZnrJx_nXETiXmspfHFpM2MlmacahOm2aSpNlXGnq37nIwUHn-VfhURsZaM9NvpRb88MpM2m7IiLqxQBXnJhW6s9tohemyoVKRExnZmPJnJJgymksFVCu5zVWbsybo5aHMM0WBH_WmU4WFLHs1ixu6N8FuPpBa1aiqpMqY2gLkx1M2WbnGcGMN10JKwb8zY7gzPn8P681Q8-Dfxh-xalRAeM5t22NZqeUqP2BV3tloMy8dJR38AFAY6kQ priority: 102 providerName: Springer Nature
Title	The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study
URI	https://link.springer.com/article/10.1186/s13023-022-02256-2 https://www.ncbi.nlm.nih.gov/pubmed/35379267 https://www.proquest.com/docview/2652165621 https://www.proquest.com/docview/2647213196 https://pubmed.ncbi.nlm.nih.gov/PMC8981747 https://doaj.org/article/12e45b570ed64589b8d8caada9e17e75
Volume	17
WOSCitedRecordID	wos000778122900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RSV dateStart: 20061201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BQYgL4k2grIzEjUZNHMd2uFG0FRy6WpWHllPkx6RdCbLVZovov-An40cSWJ4XDonk2I5GnrE94xl_A_BUZbRR2uPhFUyljCuT6oZhWmplOLM8V5kOySbEbCYXi2r-Q6ovHxMW4YHjwO3nFFmpS5Gh5ayUlZZWGqWsqjAXKAJ6qdN6BmMqrsGsLDI5XJGRfL_z7jnvr6T-KXlKt7ahgNb_OxXz10jJn9ylYRc6vAk3evWRvIhk34JL2N6Ga0e9g_wOfHVsJzjCF3dk1ZAYJE78iSs5VfhpdeYPURRRrSXBT0DCKccytnYChSTeyrogy5YoMlyeJCHDB-kwhEo_J2s8ieklSB_vvuf7kemXAPB5QQJy7V14dzh9-_JV2iddSI1T3japsUwxK1TGswJpZp19pDkazLjhxjp9rsh1aQujGcdKamMcNwVrpFCGCSVEcQ922lWLD4CYzJbKQxoiqxi6fxZonPZlmBZNbhuWQD7woDY9IrlPjPGxDpaJ5HXkW-14Vge-1TSBZ2Ofs4jH8dfWB561Y0uPpR0-OAmrewmr_yVhCewOglH3E7yrKXd6j9OFaZ7Ak7HaTU3vb1Etrs59G-bsa7_GJXA_ytFISVEWoqJcJCC2JGyL1O2adnka4L9lJZ0Z6XruDbL4naw_D8XD_zEUj-A6DZPIBy_tws5mfY6P4ar5vFl26wlcFgsR3nICVw6ms_nxJExLV5q_Ppp_cKXjN--_AZmTPVg
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLQIuvB-BAkaCE42aOI7tICHEo1VX7a72UKRyMo7ttCtBsmy2wP4Lfgm_Edt5VMujtx445JLYkeN8Mx57Zr4BeCojXMjc8eElRIaEShXmBTFhmktFiaaxjHJfbIKNx_zwMJuswc8uF8aFVXY60StqXSl3Rr6FqV1orPGB41ezL6GrGuW8q10JjQYWe2b5zW7Z6pfDd_b_PsN4Z_vg7W7YVhUIlbVOFqHSRBLNZESjxOBI2w1ATo0yEVVUaWuwJHGe6kTlhJqM50rZ4TJScCYVYZKxxL73AqwTC3Y-gPXJcDT50Ol-kiYR71JzON2qnVvQ-Umxu1Ia4pXlz1cJ-Jtp-2eE5m9uWr_67Vz73-btOlxt7Wz0uhGMG7BmyptwadRGEtyCH1Y-kOl5nmtUFaiJpkfuaBodS_O5mrnTJolkqZF3qCB_HDRtWlvJM6hJX1uiaYkk6rJMkS-FgmrjY8pfoLk5aupwoDYxYNP1Q9vfPRPqEnmK39vw_lzm4w4Myqo09wCpSKfScT8akhFj35kYZc1URXJWxLogAcQdaIRqqdtdBZFPwm_hOBUN0IQFmfBAEziA532fWUNccmbrNw6LfUtHOu5vVPMj0eowEWND0jxlkdGUpDzLueZKSi0zEzPD0gA2OgiKVhPW4hR_ATzpH1sd5hxTsjTViWtDGI7dYhDA3Qb4_UiSNGEZpiwAtiISK0NdfVJOjz1POs-43W_bnpud8JwO699Tcf_sr3gMl3cPRvtifzjeewBXsJdtF8u1AYPF_MQ8hIvq62Jazx-1ugHBx_MWq18MtqQi
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELZQQRUv3EegwCDxRqPmcGyHN46uQMCqEof6ZvmYtCtBstpsEf0X_GR8JIGFgoR4yEs8jhznszPjmfmGkEcqKxqlPR9eSVVKmTKpbiimlVaGUctylelQbILP5-LwsD74KYs_RLuPLsmY0-BZmtr13tI2cYkLttd7d5v3Pxb-qljqNuHz1BcN8vb6u4_jXkyrMhNjqsyZ_TZ-R4G1_yxV8_eIyV_cpuFvNLv8_-9xhVwaNFF4GqFzlZzD9hrZfjv42q-Tbw5BgBMTcg9dAzHeHPzhLRwr_Nwt_XmMAtVaCC4HCAcmiyjtsIkQE7xOYdGCgjEPE0KxEOgxRF0_gRUexUoVMITO7_p-sP81cIWeQiDBvUE-zPbfP3-ZDvUbUuP0wHVqLFXUcpWxrMQis87U0gwNZswwY51qWOa6sqXRlGEttDEOGJw2gitDueK8vEm22q7F2wRMZivl2RGR1hTdM0s0TpEzVPMmtw1NSD5-RmkGcnNfY-OTDEaOYDJOtXTTLMNUyyIhj6c-y0jt8VfpZx4dk6Sn5Q43utWRHFa5zAukla54hpbRStRaWGGUsqrGnCOvErIzYksOe0UvC-ZUKKdWF3lCHk7NbpV7141qsTvxMtSZ6n67TMitCMVpJGVV8rpgPCF8A6QbQ91saRfHgUlc1MJZpK7n7gjVH8P681Tc-TfxB2T74MVMvnk1f32XXCwC2H3w0w7ZWq9O8B65YL6sF_3qfli63wGFakZZ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+experiences+of+people+with+haemophilia+and+their+families+of+gene+therapy+in+a+clinical+trial+setting%3A+regaining+control%2C+the+Exigency+study&rft.jtitle=Orphanet+journal+of+rare+diseases&rft.au=Fletcher%2C+Simon&rft.au=Jenner%2C+Kathryn&rft.au=Pembroke%2C+Luke&rft.au=Holland%2C+Michael&rft.date=2022-04-04&rft.issn=1750-1172&rft.eissn=1750-1172&rft.volume=17&rft.issue=1&rft.spage=155&rft_id=info:doi/10.1186%2Fs13023-022-02256-2&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1172&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1172&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1172&client=summon